Lonza announced two acquisitions that will expand its exosomes development and manufacturing capabilities. The company will acquire the exosomes service unit from Exosomics, an extracellular vesicles biotech company, and a US-based exosomes manufacturing facility from Codiak BioSciences, a clinical-stage biopharmaceutical company specializing in exosome-based therapeutics.
Under the agreement with Exosomics, Lonza’s acquisition will include that company’s service team, service assets, and laboratories in Siena, Italy. Financial details of the deal were not disclosed. Lonza, a minority shareholder of Exosomics since 2017, will remain a shareholder after the acquisition closes.
On Nov. 2, 2021, Lonza announced two acquisitions that will expand its exosomes development and manufacturing capabilities. The company will acquire the exosomes service unit from Exosomics, an extracellular vesicles biotech company, and a US-based exosomes manufacturing facility from Codiak BioSciences, a clinical-stage biopharmaceutical company specializing in exosome-based therapeutics.
Under the agreement with Exosomics, Lonza’s acquisition will include that company’s service team, service assets, and laboratories in Siena, Italy. Financial details of the deal were not disclosed. Lonza, a minority shareholder of Exosomics since 2017, will remain a shareholder after the acquisition closes.
With the Exosomics service unit acquisition, Lonza will gain access to expertise and capabilities in extracellular vesicle analytics and characterization. In addition to R&D, Lonza will expand the service offering from the Siena site to include a comprehensive suite of development and analytical services for exosomes.
“Lonza’s acquisition reaffirms the recognition for Exosomics as a key player in Europe in the field of exosomes sciences. Exosomics will now focus on its original goal of pan-cancer screening and liquid biopsy applications in human diseases, still supported by Lonza as its most important industrial shareholder,” said Antonio Chiesi, CEO, Exosomics, in a company press release.
Under the Codiak agreement, Lonza will acquire Codiak’s Lexington, Mass., facility and become the strategic manufacturing partner for Codiak’s pipeline. Codiak will retain its pipeline of therapeutic candidates and its exosome engineering and drug-loading technologies. As part of the deal, Codiak will receive approximately $65 million of current good manufacturing practice (CGMP) manufacturing services in kind. Lonza in turn will gain worldwide access and sub-licensable rights to Codiak’s high-throughput perfusion-based CGMP process for exosome manufacturing.
Leave a Reply